Roggwil, July 26, 2021 – In 2021, the sales of the tinniwell are expected to at least double. To meet the high demand, the production start of the 5th series has been brought forward to July. This was originally planned for the late autumn of this year. The supply of the system is thus secured in the current target markets.

++ About Resaphene Suisse AG

Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology company founded in 2015 that has been selling a tinnitus therapy device under the name tinniwell since 2016.

++ Contact for further inquiries:

Resaphene Suisse AG

Ms. Anke Rauterkus (Chief Executive Officer)
Bahnhofplatz 5
9322 Egnach

Switzerland
T. +41 714500668

a.rauterkus@resaphene.ch